Leaflet KEPIVANCE 6.25mg powder for solution for injection
Indicated for: mucositis; Kawasaki disease
Route of administration: injectable
Substance: palifermin (growth hormone)
ATC: V03AF08 (Various | All other therapeutic products | Detoxifying agents for antineoplastic treatment)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Palifermin is a recombinant keratinocyte growth factor used for the prevention and treatment of severe oral mucositis in patients undergoing chemotherapy or radiotherapy for hematologic cancers. It stimulates the regeneration of epithelial cells in the oral cavity.
The medication is administered intravenously, as directed by a doctor, usually for three days before and three days after cytotoxic treatment. It is important for patients to follow the treatment regimen to reduce the risk of complications.
Patients should be aware of potential side effects, such as skin rashes, fever, or edema. It is important to inform the doctor of any unusual symptoms.
Common side effects include skin rashes, fever, and edema. In rare cases, severe reactions such as allergic reactions or mucosal hypertrophy may occur. Patients should be informed of these risks before use.
General data about KEPIVANCE 6.25mg
- Substance: palifermin
- Date of latest medicines list: 01-07-2013
- Product code: W51529001
- Concentration: 6.25mg
- Pharmaceutical form: powder for solution for injection
- Quantity: 6
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.